Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma
Stopped The study was never approved by CTEP neither was it ever activated
Conditions
- Cervical Carcinoma
- Esophageal Carcinoma
- Mucosal Melanoma
- Mucosal Melanoma of the Head and Neck
- Oral Cavity Mucosal Melanoma
- Recurrent Melanoma
- Stage II Vulvar Cancer AJCC v7
- Stage III Vulvar Cancer AJCC v7
- Stage IIIA Vulvar Cancer AJCC v7
- Stage IIIB Vulvar Cancer AJCC v7
- Stage IIIC Vulvar Cancer AJCC v7
- Stage IV Oral Cavity Cancer AJCC v6 and v7
- Stage IV Vulvar Cancer AJCC v7
- Stage IVA Oral Cavity Cancer AJCC v6 and v7
- Stage IVB Oral Cavity Cancer AJCC v6 and v7
- Stage IVC Oral Cavity Cancer AJCC v6 and v7
- Vaginal Carcinoma
Interventions
- PROCEDURE: Conventional Surgery
- BIOLOGICAL: Ipilimumab
- OTHER: Laboratory Biomarker Analysis
- BIOLOGICAL: Nivolumab
- OTHER: Patient Observation
- RADIATION: Radiation Therapy
Sponsor
National Cancer Institute (NCI)